Anna-Marie Fairhurst received her Bachelor of Science in Pharmacology at the University of Bath, UK in 1999. She received a PhD in Immunology/Pharmacology at the William Harvey Research Institute at St Bartholomew’s Hospital, University of London in 2002. During her PhD she examined the roles of FcgRIIIb and tristetraprolin (TTP) in rheumatoid arthritis. From London she moved to the National Institutes of Health, in Bethesda, Maryland and worked under the direction of Peter Lipsky in NIAMS. Her work there focused on TLR9 in a murine model of systemic lupus erythematosus (SLE) and the effects of IL-21 on B cell transcription factors. She joined the Wakeland lab in the Spring of 2004 and currently has 2 main projects. The first is determining the mechanism by which IFNa promotes kidney disease and whether specific lupus susceptibility regions are required for this effect; the second is delineating the myeloid cell lineage in murine tissue compartments using flow cytometry and examining the changes which occur in SLE.
